Company search
BioPharma Credit has an additional market quote in sterling.
Overview
Performance
Portfolio
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Engage
Data as at: 17/03/2025
In
Objective
To generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry.
AIC sector
Management group
Company website
Launch date
27/03/2017
December
Domicile
United Kingdom
Fund manager
Pedro Gonzalez de Cosio, Pablo Legorreta, Martin Friedman
Dividend frequency
Quarterly
Wind-up provisions
The Company has been established with an indefinite life, the Articles provide that a continuation vote be put to Shareholders (i) at the first AGM of the Company to be held following the fifth anniversary of Initial Admission and, if passed, at the AGM of the Company held every third year thereafter; and (ii) within two months of the expiration of any 12 month rolling period where the Shares have, on average, traded at a discount in excess of 10%. The next continuation vote will take place in 2025.
Continuation vote
3 yearly
| Market Cap (m) | Total assets (m) | Price (last close) | NAV | Discount / premium (%) | Gearing (%) | Dividend yield (%) | Dividend dates | Ongoing charge (%) |
|---|---|---|---|---|---|---|---|---|
| 1,027.54 | 1,140.18 | 0.89 | 0.98 | -9.55 | 0 | 7.87 | Mar, Jun, Sep, Dec | 1.1 (31/12/2023) |
Scroll
Note
Dividends
Dividends declared in last 12 months
| Ex-dividend date | Payment date | Dividend amount | Special dividend | Financial year |
|---|---|---|---|---|
| 30/01/2025 | 28/02/2025 | 0.018 | No | 2024 |
| 30/01/2025 | 28/02/2025 | 0.011 | Yes | 2024 |
| 26/09/2024 | 29/10/2024 | 0.018 | No | 2024 |
| 26/09/2024 | 29/10/2024 | 0.020 | Yes | 2024 |
| 04/07/2024 | 31/07/2024 | 0.018 | No | 2024 |
Scroll
Performance (%)
| Return type | 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|---|
| BioPharma Credit | Share price total return | 13.9 | 28.6 | 54.6 | N/A |
| Debt - Direct Lending AIC sector | Share price total return | 4.9 | 7.2 | 48.6 | N/A |
Scroll
Share structure
Number of shares
1,154,540,701
219,391,366
Traded volumes (number of shares)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 392,270 | 23,145,288 | 342,470,576 | 1,958,933,294 |
| Average | N/A | 1,156,540 | 1,337,420 | 1,544,070 |
Scroll
Traded values (m)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 0.35 | 20.23 | 298.97 | 1,838.84 |
| Average | N/A | 1.01 | 1.17 | 1.45 |
Scroll
Trading details
Top holdings
Data as at : 31/12/2024
| Investment | % of total assets |
|---|---|
| Collegium | 27.1 |
| Insmed | 20.9 |
| BioCryst | 12.4 |
| OptiNose | 6.8 |
| Evolus | 6.0 |
| Geron | 4.8 |
| UroGen | 4.8 |
| Novocure | 4.8 |
| BMS | 4.6 |
| Tarsus | 3.6 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.
